Best Peptides for Fat Loss and Weight Management (2026)

Every honest ranking of the best peptides for fat loss in 2026 has to answer the same three questions: how strong is the human trial evidence, how much weight loss does the compound actually produce under controlled conditions, and how legally and practically obtainable is it for a US patient right now. Rankings built on marketing copy or preclinical rodent data ignore the fact that four FDA-approved incretin agents have redefined what “meaningful weight loss” looks like since 2021. This guide ranks seven peptides used for fat loss against those three criteria, walks through the two head-to-head trials that matter most (SURMOUNT-5 and the retatrutide phase 2), covers oral versus injectable trade-offs, lays out the 2026 regulatory landscape (which changed materially with the February 27, 2026 HHS peptide reclassification and the April 2026 orforglipron approval), and closes with a Best-For-Whom framework. For per-peptide dosing detail and pharmacology see the individual guides linked throughout: Tirzepatide, Semaglutide, Retatrutide, Foundayo (orforglipron), Liraglutide, AOD-9604, and HGH Fragment 176-191.
Table of Contents
- What Makes a Peptide “Good” for Fat Loss?
- The Top 7 Peptides Ranked
- Head-to-Head: Tirzepatide vs Semaglutide
- Head-to-Head: Retatrutide vs Tirzepatide
- Oral vs Injectable GLP-1: Which Route for Whom
- 2026 Regulatory Status
- Cost Per Month Comparison
- Best-For-Whom Editorial Framework
- Frequently Asked Questions
- References
What Makes a Peptide “Good” for Fat Loss?
The single most useful concept when comparing fat-loss peptides is that not every “peptide” on the market works by the same mechanism, and mechanism largely predicts magnitude. Four mechanistic categories account for essentially every compound sold or prescribed for weight loss under a peptide framing in 2026:
1. Incretin receptor agonists (GLP-1, GIP, glucagon). Semaglutide, tirzepatide, liraglutide, and retatrutide all belong here. These molecules bind receptors that normally respond to gut hormones released after eating. Downstream effects include slowed gastric emptying (prolonged satiety after meals), central appetite suppression via hypothalamic receptor engagement, glucose-dependent insulin secretion, and (for GIP and glucagon co-agonists) modest thermogenic and lipid-oxidation effects. This mechanism produces the largest weight-loss magnitudes ever documented for pharmacologic monotherapy: 15% to 24% of total body weight over 48 to 72 weeks in phase 3 trials. Every currently FDA-approved obesity medication under a peptide framing acts through this pathway.
2. Small-molecule biased GLP-1 agonists (technically non-peptide, functionally in the same class). Orforglipron (Foundayo) is the first FDA-approved example. It engages the GLP-1 receptor with the same downstream physiology as semaglutide but with the pharmacokinetic advantages of a small molecule: oral bioavailability without empty-stomach or water restrictions, and no need for injection. Magnitude of weight loss is meaningfully lower than injectable tirzepatide or semaglutide 2.4 mg — around 12.4% at 72 weeks at the maximum tolerated dose — but the convenience is a genuine differentiator.
3. Lipolytic hGH-fragment analogs. AOD-9604 and HGH Fragment 176-191 are 16-amino-acid fragments corresponding to the C-terminal lipolytic domain of human growth hormone. The theoretical mechanism (β3-adrenergic receptor engagement driving lipolysis without engaging the somatotrophic IGF-1 axis) was reproduced in preclinical rodent and cell-line work in the early 2000s. The human clinical translation has been unimpressive: AOD-9604’s largest phase IIb trial failed to reach statistical significance versus placebo in 2007, ending pharmaceutical development. HGH Fragment 176-191 has no distinct phase 3 obesity trial base at PubMed indexing depth. Both are legally compounded again after the February 2026 HHS reclassification but neither is FDA-approved for weight loss.
4. Everything else marketed as “fat-loss peptides.” Melanotan variants, tesamorelin (an FDA-approved growth-hormone-releasing hormone analog for HIV lipodystrophy, not general obesity), CJC-1295 and ipamorelin (growth hormone secretagogues sometimes stacked with GLP-1s for body composition), and various research compounds appear in personal-use protocols. None have RCT-grade obesity data at magnitudes comparable to the GLP-1 class. They are not included in this ranking because the primary literature does not support putting them on the same list.
How we grade the evidence
This guide uses an A-through-F letter scale that is more granular than “approved / not approved” but simpler than the GRADE framework used in formal clinical guidelines. It maps roughly as follows:
| Grade | What it means | Typical evidence base |
|---|---|---|
| A | Multiple large phase 3 trials, FDA-approved, real-world data replicates trial findings, direct head-to-head against a comparator drug | SURMOUNT + SURPASS + SELECT + STEP program |
| A− | FDA-approved, phase 3 pivotal published, but shorter real-world runway or single-trial pivotal | ATTAIN-1 for orforglipron; SCALE for liraglutide |
| B+ | Phase 2 fully published, phase 3 topline positive, FDA approval anticipated but not yet granted | Retatrutide phase 2 + TRIUMPH-1 topline |
| C | Small human trials with mixed results, no phase 3 program, no FDA approval | Not represented in this ranking |
| D | Small phase II signal, larger phase IIb failed to replicate, development terminated | AOD-9604 |
| F | Preclinical (rodent, in vitro) only; no controlled human obesity trials at PubMed indexing depth | HGH Fragment 176-191 as a distinct molecule |
Evidence grade is the first filter. A “peptide that might work” (grade F) is not the same product category as a peptide with two head-to-head phase 3 trials and 17,604 patients of cardiovascular outcomes data (grade A). Any ranking that treats them as interchangeable is doing marketing, not medicine.
The Top 7 Peptides Ranked
Ranked by weight-loss magnitude in the largest published phase 3 trial, gated by evidence grade and FDA-approval status. Investigational compounds are ranked below approved compounds with equal or greater magnitude. Research peptides with grade D or lower are ranked at the bottom regardless of preclinical claims.
| Rank | Peptide | FDA status (2026) | Evidence | Peak weight loss (trial) | Route | Weekly self-pay cost (US 2026) |
|---|---|---|---|---|---|---|
| 1 | Tirzepatide (Zepbound / Mounjaro) | FDA-approved (obesity + T2D) | A | −22.5% at 15 mg / 72 wk (SURMOUNT-1) | Subcut, once weekly | ~$70 – $275 |
| 2 | Semaglutide (Wegovy / Ozempic / Rybelsus) | FDA-approved (obesity + T2D + CV risk reduction) | A | −14.9% at 2.4 mg / 68 wk (STEP 1) | Subcut weekly or oral daily | ~$35 – $325 |
| 3 | Retatrutide (LY3437943) | Investigational — phase 3 TRIUMPH ongoing | B+ | −24.2% at 12 mg / 48 wk (Phase 2) | Subcut, once weekly | N/A (not commercially available) |
| 4 | Foundayo (orforglipron) | FDA-approved April 1, 2026 (obesity) | A− | −12.4% at 36 mg / 72 wk (ATTAIN-1) | Oral, once daily | ~$75 – $125 (est.) |
| 5 | Liraglutide (Saxenda / Victoza) | FDA-approved; first generic Aug 2025 | A− | −8.0% at 3.0 mg / 56 wk (SCALE) | Subcut, once daily | ~$60 – $125 |
| 6 | AOD-9604 (Tyr-hGH176-191) | Research peptide; FDA Category 1 as of Feb 27, 2026 | D | ~−2.6 kg vs −0.8 kg placebo / 12 wk | Subcut daily (or oral) | N/A (compounded only) |
| 7 | HGH Fragment 176-191 (unmodified) | Research peptide; not FDA-approved | F | No RCT weight-loss endpoint published | Subcut (research protocols) | N/A (compounded only) |
Why tirzepatide is #1
Tirzepatide (Zepbound for obesity, Mounjaro for type 2 diabetes) is the highest-magnitude single-agent weight-loss medication currently approved for use in the United States. It is a first-in-class dual agonist of the GIP and GLP-1 receptors, engineered by Eli Lilly. The SURMOUNT-1 pivotal trial (Jastreboff et al., N Engl J Med 2022, PMID: 35658024) enrolled 2,539 adults with obesity but without diabetes and reported a mean body-weight change of approximately −22.5% at 15 mg after 72 weeks — a magnitude previously unseen in a monotherapy weight-loss trial. The SURMOUNT-2 obesity + T2D trial (Garvey et al., Lancet 2023, PMID: 37385275) confirmed −15.7% at 15 mg in a diabetic population. Direct head-to-head evidence against semaglutide in obesity (SURMOUNT-5) put tirzepatide’s 72-week weight loss at −20.2% versus semaglutide’s −13.7%, approximately 47% more weight loss in the same trial (Aronne et al., NEJM 2025, PMID: 40353578). Direct head-to-head evidence in type 2 diabetes (SURPASS-2, PMID: 34170647) showed tirzepatide 15 mg producing −11.2 kg weight loss versus semaglutide 1 mg at −5.7 kg. See our Tirzepatide Guide for full pharmacology.
Why semaglutide is #2, not #1
Semaglutide (Wegovy for obesity, Ozempic for T2D, Rybelsus and oral Wegovy for oral use) is the most-studied GLP-1 in the world and remains the correct first-line choice in specific patient populations — particularly patients with established cardiovascular disease, given the SELECT trial’s demonstration of a 20% relative reduction in major adverse cardiovascular events in obesity without diabetes (Lincoff et al., NEJM 2023, PMID: 37952131). But on pure weight-loss magnitude in the general obesity population, semaglutide loses to tirzepatide by roughly 6.5 percentage points at 72 weeks. The STEP 1 pivotal trial reported −14.9% weight loss at 2.4 mg over 68 weeks (Wilding et al., NEJM 2021, PMID: 33567185). Semaglutide’s advantages over tirzepatide are the longer real-world safety runway (approved for obesity in 2021 versus 2023), the unique cardiovascular outcome data, and the availability of both weekly injection and daily oral formulations. See our Semaglutide Guide.
Why retatrutide is #3 despite the highest magnitude
Retatrutide (LY3437943) is a triple agonist at the GIP, GLP-1, and glucagon receptors. The glucagon receptor arm adds a thermogenic and hepatic-lipid-oxidation component that the pure GIP+GLP-1 mechanism of tirzepatide lacks. The Phase 2 obesity trial (Jastreboff et al., NEJM 2023, PMID: 37366315) enrolled 338 subjects and reported −24.2% weight loss at 12 mg at 48 weeks — a magnitude at phase 2 that exceeds tirzepatide’s phase 3 SURMOUNT-1 result. Topline readouts from the TRIUMPH phase 3 program are consistent: TRIUMPH-4 (osteoarthritis + obesity) reported −28.7% at 12 mg over 68 weeks in the December 2025 press release, and TRIUMPH-1 (obesity) topline in May 2026 confirmed all doses hit the primary endpoint. But retatrutide is investigational as of publication — no FDA approval, no commercial availability, no verified compounded product. Anticipated BLA filing late 2026 / early 2027 based on Lilly investor calls. Any “retatrutide” sold today by research peptide vendors is not the same molecule as Lilly’s LY3437943; there is no purity or potency verification pathway. See our Retatrutide Guide. TRIUMPH-1 and TRIUMPH-4 full manuscript PMIDs remain [VERIFY] pending publication.
Why Foundayo (orforglipron) is #4
Foundayo (orforglipron, LY3502970) received FDA approval on April 1, 2026 for chronic weight management in adults with obesity or overweight plus at least one weight-related comorbidity. It is the first oral small-molecule GLP-1 receptor agonist approved for obesity. Note the date: the December 2025 oral GLP-1 obesity approval was Novo Nordisk’s oral Wegovy 25 mg tablet (semaglutide), a completely different molecule. Do not conflate. The ATTAIN-1 pivotal trial (Wharton et al., NEJM 2025, PMID: 40960239) enrolled 3,127 adults with obesity and reported −7.8% (6 mg), −9.3% (12 mg), and −12.4% (36 mg) weight loss at 72 weeks versus −2.1% placebo. The 36 mg dose absolute loss was −27.3 lbs. Foundayo’s ceiling is meaningfully below injectable tirzepatide (−22.5%) or injectable semaglutide 2.4 mg (−14.9%), and it does not yet have cardiovascular outcomes data. Its differentiator is convenience: a small-molecule pill with no food or water restriction. For injection-averse patients this is a genuine breakthrough. See our Foundayo (Orforglipron) Guide.
Why liraglutide is #5
Liraglutide (Saxenda for obesity, Victoza for T2D) was the first-generation daily-injection GLP-1 agonist, approved by the FDA in 2010 (T2D) and 2014 (obesity). The SCALE Obesity trial (Pi-Sunyer et al., NEJM 2015, PMID: 26132939) reported −8.0% weight loss at 3.0 mg over 56 weeks — meaningful, but roughly half the magnitude of weekly semaglutide or tirzepatide. Liraglutide is being progressively outclassed by the weekly options for most patients, but it retains three important niches: it is the only GLP-1 with a labeled indication for pediatric obesity (ages 12-17), the daily-injection ritual can help some patients build adherence in a way weekly dosing does not, and the first generic version was approved in August 2025, which will progressively drive cost down. See our Liraglutide Guide.
Why AOD-9604 is #6
AOD-9604 is a synthetic 16-amino-acid fragment corresponding to residues 176-191 of human growth hormone with a tyrosine N-terminal substitution for stability. The preclinical mechanism work (Heffernan et al., Endocrinology 2001, PMID: 11713213; Ng et al., Horm Res 2000, PMID: 11146367) demonstrated β3-adrenergic-receptor-dependent lipolysis in mouse models without engaging the somatotrophic IGF-1 axis, meaning the lipolytic effect is theoretically decoupled from growth-hormone side effects. Metabolic Pharmaceuticals (Australia) advanced AOD-9604 through six phase II human trials during the early 2000s. Development was terminated in 2007 after the largest phase IIb trial failed to demonstrate statistical significance versus placebo on the primary weight-loss endpoint. AOD-9604 has been used continuously in the research-peptide and compounding-pharmacy space since then; the February 27, 2026 HHS reclassification restored its FDA Category 1 status, allowing 503A compounded prescribing. Reclassification is not approval — it means “not banned from compounding,” not “shown to work.” Honest framing: AOD-9604 appears safe in human trials, but the effect magnitude in the small phase II data (roughly −2.6 kg versus −0.8 kg placebo over 12 weeks) is a small fraction of what GLP-1s produce over comparable timeframes. See our AOD-9604 Guide.
Why HGH Fragment 176-191 is #7
HGH Fragment 176-191 is the unmodified 16-amino-acid C-terminal fragment of human growth hormone (the same 176-191 residues that AOD-9604 covers, but without the Tyr N-terminal substitution). The two molecules are frequently marketed interchangeably by research peptide vendors — they are not identical. AOD-9604 was the molecule Metabolic Pharmaceuticals advanced through clinical trials, not HGH Fragment 176-191. There is no distinct RCT with a weight-loss primary endpoint using HGH Fragment 176-191 (as opposed to AOD-9604) at PubMed indexing depth. Vendor marketing that cites the AOD-9604 papers as evidence for HGH Fragment 176-191 is not scientifically correct — the compounds are related, not identical, and their published trial bases do not transfer between molecules. HGH Fragment 176-191 is not FDA-approved for any indication. See our HGH Fragment 176-191 Guide. Honest bottom line: AOD-9604 has more literature; HGH Fragment 176-191 does not have its own trial base.
Head-to-Head: Tirzepatide vs Semaglutide
This is the single most important comparison in the fat-loss peptide space, and it was settled in 2025 by the SURMOUNT-5 trial. Every ranking that omits SURMOUNT-5 is out of date.
Trial design. SURMOUNT-5 (Aronne LJ, Horn DB, le Roux CW, et al; SURMOUNT-5 Trial Investigators. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025 Jul 3;393(1):26-36. doi:10.1056/NEJMoa2416394. PMID: 40353578, epub 2025 May 11) was a phase 3b, open-label, randomized 1:1, 72-week head-to-head trial in 751 adults with obesity but without type 2 diabetes. Tirzepatide was titrated to maximum tolerated dose (10 or 15 mg weekly). Semaglutide was dosed at the approved obesity dose of 2.4 mg weekly. Both arms received behavioral support programming.
Result at 72 weeks. Mean body-weight change was −20.2% for tirzepatide versus −13.7% for semaglutide. Least-squares mean difference −6.5 percentage points (95% CI −8.0 to −5.0, p<0.001). Tirzepatide was superior on every prespecified secondary endpoint including waist circumference and the proportion of participants hitting each of the ≥5%, ≥10%, ≥15%, ≥20%, and ≥25% weight-loss thresholds. Serious adverse events were similar in both arms (4.8% tirzepatide vs 3.5% semaglutide). GI events dominated as expected in the class. Discontinuation for adverse events was numerically lower with tirzepatide (6.1% vs 8.0%), consistent with earlier trial data suggesting the dual-agonist may be marginally better tolerated at maximum dose than pure GLP-1 agonism.
Real-world corroboration. Retrospective EHR cohort analyses have consistently reproduced the directional finding, though the magnitude of the gap tends to narrow in real-world unblinded conditions where adherence is imperfect. The Truveta cohort (JAMA Internal Medicine, July 2024) reported tirzepatide −11.15% versus semaglutide −8.83% at 6 months in n=2,396 on-treatment patients. The Richards et al. 12-month remote-weight-management cohort (JMIR Form Res. 2025 Sep 12;9:e81912. doi:10.2196/81912. PMID: 40838489) reported 95.2% of tirzepatide patients hitting ≥10% weight loss versus 83.1% of semaglutide patients, and 83.7% versus 56.2% at the ≥15% threshold. Truveta full-paper PMID marked [VERIFY EXACT PMID].
Editorial takeaway. For pure weight-loss magnitude, tirzepatide wins by approximately 6.5 percentage points at 72 weeks in the largest and cleanest head-to-head trial. Semaglutide retains its position for patients with established cardiovascular disease (SELECT), for patients on the oral formulation (Rybelsus or oral Wegovy 25 mg tab), and for physicians who prefer its longer real-world safety runway. Both are grade A. Both are correct choices depending on the patient. See our Tirzepatide vs Semaglutide comparison for the full breakdown.
Head-to-Head: Retatrutide vs Tirzepatide
No direct randomized head-to-head trial of retatrutide versus tirzepatide has been published or is currently enrolling. The comparison must be built from cross-trial data, with all the standard caveats: different patient populations, different trial designs, different lengths of follow-up. That said, the phase 2 retatrutide numbers are striking enough that a mechanistic case can be built.
Retatrutide phase 2 at 48 weeks: −24.2% at 12 mg, −22.8% at 8 mg (combined), −17.5% at 4 mg, −8.7% at 1 mg, all versus −2.1% placebo (Jastreboff et al., NEJM 2023, PMID: 37366315). Trial n=338.
Tirzepatide phase 3 SURMOUNT-1 at 72 weeks: −22.5% at 15 mg (Jastreboff et al., NEJM 2022, PMID: 35658024). Trial n=2,539.
Head-to-head comparison, with caveats. Retatrutide at 12 mg produced approximately 1.7 percentage points more weight loss at 48 weeks than tirzepatide at 15 mg produced at 72 weeks — despite being 24 weeks shorter. TRIUMPH-4 topline data extend this to −28.7% at 12 mg over 68 weeks in an osteoarthritis + obesity population (December 2025 topline, full manuscript [VERIFY]). If TRIUMPH-1 confirms this magnitude in a general obesity population when the full manuscript is published, retatrutide will have demonstrated the largest single-agent weight loss of any injectable in the phase 3 literature. The mechanistic rationale is straightforward: glucagon-receptor agonism adds a thermogenic + hepatic-lipid-oxidation component that neither tirzepatide (GIP + GLP-1) nor semaglutide (GLP-1 alone) engages.
Tolerability tradeoff. TRIUMPH-1 topline flagged an 11.3% AE-driven discontinuation rate at the high dose (versus 4.9% placebo). This is higher than SURMOUNT-1’s tirzepatide 15 mg discontinuation figure. The glucagon-receptor component likely magnifies GI adverse events and adds theoretical (small in phase 2 data) hepatic and glycemic considerations. Long-term safety data does not yet exist because the drug has never been on the commercial market.
Editorial takeaway. Retatrutide is the peptide to watch, not the peptide to use in 2026. When FDA approval lands (anticipated 2027), it will very likely displace tirzepatide as the highest-magnitude approved option. Until then, the correct posture is: read the publications when they land, do not attempt to source “retatrutide” from research peptide vendors (the compound is not the same as Lilly’s LY3437943 and has no purity or potency verification pathway), and if you are in a TRIUMPH extension trial, stay in the trial. See our Retatrutide vs Tirzepatide comparison for the full analysis.
Oral vs Injectable GLP-1: Which Route for Whom
Oral GLP-1 options for weight loss meaningfully expanded in late 2025 and early 2026. As of publication there are three FDA-approved oral GLP-1 products in the US market, each with a different profile.
| Product | Molecule | Dose | Restriction | Peak weight loss (trial) | Approved for |
|---|---|---|---|---|---|
| Foundayo | Orforglipron (small molecule) | 6 / 12 / 36 mg PO daily | None — take any time, with or without food/water | −12.4% at 36 mg / 72 wk (ATTAIN-1) | Chronic weight management (approved Apr 1, 2026) |
| Rybelsus | Semaglutide (peptide) | 3 / 7 / 14 mg PO daily | Empty stomach + 30 min fast + limited water | Data primarily in T2D populations | Type 2 diabetes (approved 2019) |
| Oral Wegovy 25 mg | Semaglutide (peptide, high-dose tab) | 25 mg PO daily (titrated) | Empty stomach + 30 min fast + limited water | [VERIFY — OASIS-4 magnitude publication pending] | Chronic weight management (approved Dec 2025) |
Injectable GLP-1s remain the highest-magnitude option. Tirzepatide 15 mg produces −22.5% weight loss at 72 weeks. Injectable semaglutide 2.4 mg produces −14.9% at 68 weeks. Both meaningfully exceed the ceiling of any currently approved oral GLP-1 (Foundayo −12.4%). If your primary goal is maximum weight loss and you can tolerate weekly self-injection, the injectable route is superior. See our Reconstitution Beginner Guide and Peptide Timing Guide for injection technique and scheduling.
Choose oral when the trade-off makes sense for you. The Foundayo differentiator is the total absence of dosing restriction: no food restriction, no water restriction, no injection burden, once daily at any time. Rybelsus and oral Wegovy retain the semaglutide efficacy signature (higher than Foundayo) but require an empty stomach and a 30-minute pre-meal fast, which is a real adherence tax. For patients with severe needle phobia, unstable injection-site access (e.g., certain occupational or travel situations), or a strong preference for pill-based medication, Foundayo is the most convenient available option and its 12.4% ceiling is still clinically meaningful. For patients who want oral dosing plus the largest possible oral-dose weight loss, oral Wegovy 25 mg is the choice, at the cost of the empty-stomach protocol.
Cost also skews toward oral in some scenarios. Novo Nordisk’s introductory promotional pricing on oral Wegovy 4 mg (approximately $149/month through August 31, 2026, per current Novo self-pay listings) is significantly cheaper than either compounded or self-pay branded injectable options for many patients. Once the promotional pricing ends, oral list pricing is likely to normalize toward injectable list pricing.
2026 Regulatory Status
The 2026 landscape reflects two entirely separate regulatory tracks. Do not conflate them.
Track 1: FDA-approved incretin drugs. Tirzepatide (approved Mounjaro May 2022, Zepbound November 2023), semaglutide (Ozempic Dec 2017, Rybelsus Sept 2019, Wegovy June 2021, cardiovascular indication March 2024, oral Wegovy 25 mg December 2025), liraglutide (Victoza 2010, Saxenda 2014, first generic August 2025), and orforglipron (Foundayo April 1, 2026). All are FDA-approved drugs on the standard prescription pathway. Compounded versions of tirzepatide and semaglutide became broadly restricted after both molecules came off the FDA drug-shortage list in 2024-2025. The April 30, 2026 FDA proposal to remove GLP-1 receptor agonists from the 503B bulks list eliminated large-scale compounding authorization for the class. Compounded semaglutide and compounded tirzepatide remain available only through narrow 503A pathways (clinically necessary variations, allergies to inactive ingredients, non-standard strengths). Retatrutide is investigational and not compoundable; BLA filing anticipated late 2026 or early 2027.
Track 2: Research peptides on the FDA Category 1/2 framework. AOD-9604 was on the Category 2 restricted list from 2023 to February 27, 2026, then reclassified back to Category 1 as part of the HHS Secretary Kennedy peptide framework revision that restored approximately 14 peptides from restriction. Category 1 status allows 503A compounding pharmacies to prepare AOD-9604 by physician prescription; it is not approval for any indication. HGH Fragment 176-191 is not explicitly listed on either published Category list at indexing depth — treat as “not FDA-approved for any indication.” The July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) review covered seven research peptides — BPC-157, TB-500, Epitalon, Semax, Emideltide, and two others — and did NOT cover AOD-9604, HGH Fragment 176-191, or any of the incretin drugs. The GLP-1 regulatory track and the research peptide regulatory track have entirely different stakeholders, timelines, and stakes.
| Peptide | Regulatory status (July 2026) | Legal path to obtain |
|---|---|---|
| Tirzepatide | FDA-approved (Mounjaro T2D, Zepbound obesity). Compounding restricted after shortage resolution. | Prescription from licensed clinician; branded pen or narrow 503A compounded exception |
| Semaglutide | FDA-approved (Ozempic, Wegovy, Rybelsus, oral Wegovy 25 mg tab). Compounding restricted after shortage resolution. | Prescription from licensed clinician; branded or narrow 503A |
| Retatrutide | Investigational. Phase 3 TRIUMPH program in progress. Not compoundable. | Clinical trial enrollment only; no commercial pathway |
| Foundayo (orforglipron) | FDA-approved April 1, 2026 for chronic weight management | Prescription from licensed clinician |
| Liraglutide | FDA-approved (Victoza T2D, Saxenda obesity). First generic August 2025. | Prescription from licensed clinician; generic increasingly available |
| AOD-9604 | Research peptide; FDA Category 1 as of Feb 27, 2026 (allows 503A compounding). No FDA approval for any indication. | Prescription + 503A compounding pharmacy |
| HGH Fragment 176-191 | Research peptide; not FDA-approved. Not explicitly listed on either published FDA Category list. | No compliant compounding pathway; research-only vendors operate outside FDA oversight |
Cost Per Month Comparison
All prices are US market, 2026, in USD. Ranges reflect the spread between list price at branded pharmacy and manufacturer self-pay direct programs. Insurance coverage varies widely — many commercial plans cover Wegovy and Zepbound for eligible obesity patients, and Medicare Part D introduced a “Bridge” program for July 2026 through December 2027 that caps eligible-patient cost at approximately $50/month for select GLP-1s. Verify current pricing directly with the manufacturer and pharmacy for your specific situation.
| Peptide | List price (branded) | Manufacturer self-pay direct | With insurance + savings card | Compounded (where legal) |
|---|---|---|---|---|
| Tirzepatide (Zepbound) | ~$1,080/mo (pen) | $299 – $449/mo (LillyDirect vial) | As low as $25/mo | Not broadly available post-shortage |
| Semaglutide (Wegovy) | ~$1,349/mo | $349/mo (standard); $149/mo (oral 4 mg introductory) | As low as $0/mo (Wegovy) or $25/mo (Ozempic) | Not broadly available post-shortage |
| Retatrutide | Not commercially available | N/A | N/A — trial enrollment only | Not compoundable |
| Foundayo (orforglipron) | Est. $800 – $1,000/mo | Est. $300 – $500/mo (final Lilly self-pay pricing rolling out mid-late 2026) | Anticipated similar to Zepbound structure | Not compoundable — patented small molecule |
| Liraglutide (Saxenda / generic) | ~$1,347/mo (Saxenda list) | Generic $230 – $500/mo; GoodRx coupon ~$372/mo | $25 – $60/mo | Generic increasingly available; compounded generally not |
| AOD-9604 | No FDA-approved product | N/A | N/A | Compounded via 503A pharmacy; pricing not standardized |
| HGH Fragment 176-191 | No FDA-approved product | N/A | N/A | Research-vendor only; not a compliant compounding path |
Note on research peptides. Per our editorial policy, we do not link research peptide vendors as affiliates for AOD-9604, HGH Fragment 176-191, or any research peptide. Compounding pharmacy sourcing via prescription is the only recommended path for any peptide administered to humans. For compounded AOD-9604 (Category 1 as of February 2026), a legitimate 503A pharmacy with a physician prescription is the compliant path.
Note on price volatility. The GLP-1 space is repricing aggressively in 2026 as Lilly and Novo compete on self-pay direct programs and as insurance formularies adapt. Foundayo self-pay pricing was still rolling out at the time of publication. Any price listed here can move materially within 60-90 days. Verify with the manufacturer or your pharmacy before making a purchasing decision.
Where-to-buy detail for the FDA-approved options: Tirzepatide, Semaglutide, Foundayo.
Best-For-Whom Editorial Framework
Ranking gives you the average answer. The correct answer for a given patient depends on goals, constraints, comorbidities, and personal preferences. This is our decision-tree, drafted for informed patients preparing to discuss options with their prescribing clinicians.
If your primary goal is the largest possible weight loss with the strongest evidence base, and you are willing to inject once a week: Choose tirzepatide (Zepbound). SURMOUNT-5 documented 47% more weight loss than semaglutide over 72 weeks. SURMOUNT-1 showed up to 22.5% total body weight loss at 15 mg. This is the highest-magnitude currently-approved single-agent option.
If you have established cardiovascular disease and want a weight-loss drug with proven CV outcome benefit: Choose semaglutide (Wegovy). The SELECT trial (n=17,604) documented a 20% relative reduction in major adverse cardiovascular events with semaglutide 2.4 mg. Tirzepatide has no completed CV outcomes trial yet.
If you strongly prefer an oral pill and can accept a lower magnitude ceiling on weight loss: Choose Foundayo (orforglipron) — no food or water restriction, once daily at any time, up to −12.4% at 72 weeks. Second-best oral option: oral Wegovy 25 mg tab for a modestly higher magnitude at the cost of the empty-stomach protocol.
If cost is the primary constraint and you have limited insurance coverage: Consider generic liraglutide ($230–$500/mo baseline, $25–$60/mo with commercial insurance + savings card) or Wegovy self-pay ($349/mo through Novo). Cheapest FDA-approved GLP-1 pathway is generic liraglutide with a Teva savings card, though the efficacy ceiling is meaningfully lower than tirzepatide/semaglutide.
If you have both obesity and type 2 diabetes: Tirzepatide is the correct first-line choice. SURPASS-2 demonstrated superiority over semaglutide 1 mg on both A1C reduction (−2.30% at 15 mg vs −1.86%) and weight loss (−11.2 kg vs −5.7 kg) in a T2D population.
If you are pediatric (age 12-17) with obesity: Liraglutide (Saxenda) is the only GLP-1 with a labeled pediatric obesity indication. Semaglutide and tirzepatide do not.
If you are enrolled in a Lilly TRIUMPH extension trial for retatrutide: Stay in the trial. You are getting the highest-magnitude molecule in phase 3, for free, with rigorous clinical monitoring. Do not attempt to source “retatrutide” from research peptide vendors — the vendor compound is not verified as identical to Lilly’s LY3437943, has no purity or potency guarantee, and there is no established compliant pathway.
If you cannot tolerate GLP-1 receptor agonist side effects or have contraindications (personal or family history of medullary thyroid carcinoma, MEN2 syndrome, prior severe pancreatitis): The evidence base for a peptide alternative that produces comparable weight loss is very thin. AOD-9604 has the largest evidence base among non-GLP-1 lipolytic peptides, but the magnitude (~2 kg over 12 weeks in the small phase II data) is a fraction of GLP-1 magnitude. Lifestyle intervention (moderate caloric deficit, resistance training, adequate protein) remains the evidence-based fallback and should be the anchor of any weight-management strategy regardless of pharmacology.
If you are curious about AOD-9604 or HGH Fragment 176-191 as adjuncts or alternatives: Understand what the evidence supports and does not. AOD-9604 development was terminated in 2007 after phase IIb failed. HGH Fragment 176-191 has no distinct RCT trial base at PubMed indexing depth. Neither is FDA-approved for obesity. Compounded pricing is not standardized. Efficacy at claimed doses is not confirmed at trial-quality level. If you elect to use one, AOD-9604 has more literature and is the more defensible choice; source only through a licensed 503A compounding pharmacy with a physician prescription.
If you want to stack a GLP-1 with a healing peptide for muscle preservation: See our Fat Loss Stack Guide for the tirzepatide + BPC-157 protocol with three variants (standard, aggressive, conservative).
Frequently Asked Questions
What is the single most effective peptide for fat loss in 2026?
Tirzepatide (Zepbound / Mounjaro). It produced the largest weight loss of any currently FDA-approved single-agent obesity medication in phase 3 trials: −22.5% at 15 mg over 72 weeks in SURMOUNT-1. It also won a direct head-to-head against semaglutide in SURMOUNT-5 (−20.2% versus −13.7% at 72 weeks). Retatrutide (investigational) may exceed tirzepatide’s magnitude if the TRIUMPH-1 full manuscript confirms the topline, but retatrutide is not commercially available as of publication.
How much weight can I realistically lose on tirzepatide?
SURMOUNT-1 pivotal trial data at 72 weeks: −22.5% mean weight loss at 15 mg maximum dose in patients with obesity but without diabetes (Jastreboff et al., NEJM 2022, PMID: 35658024). SURMOUNT-2 in patients with obesity and type 2 diabetes: −15.7% at 15 mg. Real-world weight loss tends to be slightly lower than trial weight loss because adherence and titration compliance are imperfect outside a clinical trial. A reasonable expectation range at 12-15 mg maintenance dose with adequate dietary and activity support is 15% to 22% of body weight over 12-18 months. Weight regain after discontinuation is well documented — see the FAQ on stopping the drug below.
Is Foundayo (orforglipron) really approved, or was that the oral Wegovy?
Both are approved, and they are different molecules from different companies. Foundayo (Eli Lilly’s orforglipron, small molecule) received FDA approval on April 1, 2026 for chronic weight management. Oral Wegovy 25 mg tablet (Novo Nordisk’s semaglutide, high-dose oral formulation) received FDA approval in December 2025 for chronic weight management. Both are oral once-daily GLP-1 receptor agonists. Foundayo is a small-molecule non-peptide; oral Wegovy 25 mg is a peptide (same molecule as injectable Wegovy at a higher oral dose). Foundayo has no dosing restrictions; oral Wegovy 25 mg requires an empty stomach and a 30-minute pre-meal fast.
When will retatrutide be FDA-approved?
Lilly investor calls anticipate BLA filing in late 2026 or early 2027 based on the completed TRIUMPH-1 and TRIUMPH-4 topline results. FDA action typically follows BLA filing by 10-12 months, meaning approval could arrive late 2027 at the earliest. TRIUMPH-2 (obesity + T2D) and TRIUMPH-3 (obesity + established CV disease) readouts are expected late 2026 / early 2027, and their outcomes may inform the specific indications on the label. Any timeline before 2027 is speculative.
Are AOD-9604 and HGH Fragment 176-191 the same thing?
No, though they are frequently marketed interchangeably. AOD-9604 is a 16-amino-acid synthetic fragment corresponding to residues 176-191 of human growth hormone plus an N-terminal tyrosine substitution added for stability (Tyr-hGH176-191). HGH Fragment 176-191 is the same 176-191 residues without the tyrosine substitution. AOD-9604 was the molecule Metabolic Pharmaceuticals advanced through six phase II human trials in the early 2000s. HGH Fragment 176-191 does not have its own distinct set of controlled human obesity trials at PubMed indexing depth. Any vendor citing AOD-9604 trial data as evidence for HGH Fragment 176-191 is conflating two related but distinct molecules.
What happens if I stop taking a GLP-1?
Weight regain is well documented. The STEP-4 extension study reported that patients discontinued from semaglutide regained approximately two-thirds of their lost weight within one year. Similar patterns are anticipated with tirzepatide, though the specific extension data are still accumulating. The clinical consequence is that GLP-1 therapy for obesity is generally viewed as long-term or indefinite at a maintenance dose (5-15 mg tirzepatide weekly, 1.7-2.4 mg semaglutide weekly), analogous to statin therapy for hyperlipidemia. Stopping cold typically results in appetite return, gradual weight regain, and (unfortunately) some of the muscle mass lost during aggressive loss may be replaced by fat rather than lean tissue. Discontinuation decisions should be made in consultation with the prescribing physician.
Do I need to stop tirzepatide or semaglutide before surgery?
Yes. The American Society of Anesthesiologists 2023 consensus recommends holding once-weekly GLP-1s for 7 days prior to elective procedures under general anesthesia [VERIFY — ASA 2023 statement]. The concern is aspiration risk from delayed gastric emptying. Discuss with your surgeon and anesthesiologist. The same rule applies to Foundayo (orforglipron) and other daily oral GLP-1s, though holding periods are typically shorter for daily-dose formulations — verify with your care team.
Which fat-loss peptide is cheapest?
Depends on insurance and eligibility. If you have commercial insurance with GLP-1 coverage and are eligible for a manufacturer savings card, semaglutide (Wegovy) and tirzepatide (Zepbound) can both come in at $25/month or less. Without insurance, the cheapest FDA-approved pathway is generic liraglutide via a Teva savings card ($20-60/month for eligible patients), though the efficacy ceiling is meaningfully lower. For patients paying self-pay direct, LillyDirect Zepbound vials at $299/month (2.5-5 mg) is the cheapest branded tirzepatide access; Novo self-pay Wegovy at $349/month is the branded semaglutide equivalent. Foundayo (orforglipron) final self-pay pricing was still rolling out at time of publication, with analyst estimates in the $300-500/month range.
Can I combine a fat-loss peptide with other peptides?
The most common combination is tirzepatide or semaglutide plus BPC-157 for muscle preservation and GI tolerability during aggressive weight loss. See our Fat Loss Stack Guide for the full protocol with three variants (standard, aggressive, conservative), reconstitution math, and cost breakdown. Adding a third or fourth peptide (CJC-1295, ipamorelin, tesamorelin) compounds cost, injection burden, side-effect risk, and monitoring requirements — not recommended without physician oversight.
What labs should I get before starting a GLP-1 for fat loss?
Baseline standard-of-care panel typically includes: fasting glucose, HbA1c, comprehensive metabolic panel (kidney and liver function), lipid panel, thyroid panel (TSH minimum), and CBC. If you are considering an aggressive weight-loss protocol, a baseline DEXA body composition scan is useful for tracking lean-mass retention. Repeat labs at approximately 12 weeks and every 6 months during maintenance. Personal or family history of medullary thyroid carcinoma or MEN2 syndrome is a contraindication to all GLP-1 receptor agonists and should be flagged before starting. See our Peptide Lab Testing Guide for the recommended baseline panel and follow-up schedule.
References
All PMIDs below have been independently verified via the NCBI E-utilities esummary endpoint (which returns structured JSON metadata bypassing the reCAPTCHA challenge on the PubMed browser interface). Items marked [VERIFY] are pending secondary confirmation per Rule 530 of the project’s editorial standard.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi:10.1056/NEJMoa2206038. PMID: 35658024.
- Garvey WT, Frias JP, Jastreboff AM, et al; SURMOUNT-2 Investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes. Lancet. 2023 Aug 19;402(10402):613-626. doi:10.1016/S0140-6736(23)01200-X. PMID: 37385275.
- Aronne LJ, Horn DB, le Roux CW, et al; SURMOUNT-5 Trial Investigators. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025 Jul 3;393(1):26-36. doi:10.1056/NEJMoa2416394. PMID: 40353578.
- Frías JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 5;385(6):503-515. doi:10.1056/NEJMoa2107519. PMID: 34170647.
- Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi:10.1056/NEJMoa2032183. PMID: 33567185.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi:10.1056/NEJMoa2307563. PMID: 37952131.
- Jastreboff AM, Kaplan LM, Frías JP, et al; Retatrutide Phase 2 Obesity Trial Investigators. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023 Aug 10;389(6):514-526. doi:10.1056/NEJMoa2301972. PMID: 37366315.
- Wharton S, Aronne LJ, Stefanski A, et al; ATTAIN-1 Trial Investigators. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025 Nov 6;393(18):1796-1806. doi:10.1056/NEJMoa2511774. PMID: 40960239.
- Pi-Sunyer X, Astrup A, Fujioka K, et al; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015 Jul 2;373(1):11-22. doi:10.1056/NEJMoa1411892. PMID: 26132939.
- Richards R, Lunt W, Whitman M, et al. Semaglutide and Tirzepatide in a Remote Weight Management Program: 12-Month Retrospective Observational Study. JMIR Form Res. 2025 Sep 12;9:e81912. doi:10.2196/81912. PMID: 40838489.
- Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001 Dec;142(12):5182-9. doi:10.1210/endo.142.12.8522. PMID: 11713213.
- Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-8. doi:10.1159/000053183. PMID: 11146367.
- Cox HD, Smeal SJ, Hughes CM, et al. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2015 Jan;7(1):31-8. doi:10.1002/dta.1715. PMID: 25208511.
- Wharton S, Batterham RL, Bhatta M, et al. ACHIEVE-1: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025;393(19):1860-1873. doi:10.1056/NEJMoa2505669. [PMID VERIFY — DOI confirmed; PMID pending secondary lookup.]
- Truveta retrospective EHR cohort — real-world tirzepatide vs semaglutide weight loss at 6 months. JAMA Intern Med. 2024. doi:10.1001/jamainternmed.2024.2525. [PMID VERIFY].
- TRIUMPH-1 (retatrutide phase 3 obesity, n=2,339). Topline announced May 2026. NCT05929066. [Full manuscript PMID pending publication].
- TRIUMPH-4 (retatrutide phase 3 osteoarthritis + obesity). Topline announced December 2025. [Full manuscript PMID pending publication].
- American Society of Anesthesiologists. Consensus-based guidance on preoperative management of patients on GLP-1 receptor agonists. June 2023. [VERIFY — ASA 2023 statement].
- US Department of Health and Human Services. Peptide framework revision restoring 14 peptides from Category 2 to Category 1. February 27, 2026 announcement. [VERIFY — HHS reclassification document].
Last reviewed 2026-07-12 by New Science Labs LLC. This article is educational and does not constitute medical advice. Regulatory status, pricing, and trial data reflect the July 2026 landscape and may change materially over subsequent quarters.
—






